Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509671 | 0.91 | ALDH1A1 (0.46) | SLC7A5CYP1A2CYP2C19ALDH1A1 | |
| Acetic Acid SCHEMBL27734248 | 0.85 | BCL2 (0.56) | BCL2SMN1; SMN2MAPTPTGS2MGLL | |
| SCHEMBL729924 | 0.83 | AKR1B1 (0.58) | KMT2ALMNAHTTMAPTHPGD | |
| SCHEMBL13554933 | 0.83 | ENPP2 (0.44) | SMN1; SMN2SLC7A5ALDH1A1TSHR | |
| SCHEMBL1515871 | 0.83 | AKR1B1 (0.58) | BCL2LMNAHTTMAPTPTGS2 | |
| SCHEMBL6616564 | 0.83 | TP53 (0.44) | BCL2SMN1; SMN2KMT2ALMNAHTT | |
| SCHEMBL12081769 | 0.82 | RXRA (0.44) | BCL2KMT2APTGS2ALDH1A1GAA | |
| SCHEMBL2305032 | 0.82 | BCL2 (0.59) | BCL2LMNAHTTPTGS2GAA | |
| SCHEMBL17430659 | 0.82 | BCL2 (0.46) | BCL2SMN1; SMN2KMT2ALMNAHTT | |
| SCHEMBL21574300 | 0.82 | SLC7A5 (0.41) | SLC7A5CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117250289-A | Method for detecting content of p-methyl propiophenone in sample | 湖南新领航检测技术有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-119330913-A | Preparation method of eperisone hydrochloride | 康普药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | BCL2 4621/4885SMN1; SMN2 3760/4885KMT2A 3393/4885 |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | BCL2 2944/4885SMN1; SMN2 2304/4885KMT2A 2321/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | BCL2 2373/4885SMN1; SMN2 1782/4885KMT2A 2517/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | BCL2 3090/4885SMN1; SMN2 4722/4885KMT2A 4447/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | BCL2 2002/4885SMN1; SMN2 3745/4885KMT2A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.